Alisol B regulates AMPK/mTOR/SREBPs via directly targeting VDAC1 to alleviate hyperlipidemia

• Published in: Phytomedicine (Stuttgart) 2024-06, Vol.128, p.155313-155313, Article 155313
• Main Authors: Gao, Gai, Zhao, Jie, Ding, Jing, Liu, Shuyan, Shen, Yanyan, Liu, Changxin, Ma, Huifen, Fu, Yu, Xu, Jiangyan, Sun, Yiran, Zhang, Xiaowei, Zhang, Zhenqiang, Xie, Zhishen
• Format: Article
• Language: English
• Subjects: Alisma - chemistry; Alisol B; AMP-Activated Protein Kinases - metabolism; Animals; Cholestenones - pharmacology; Hep G2 Cells; Hepatocytes - drug effects; Hepatocytes - metabolism; Humans; Hyperlipidemia; Hyperlipidemias - drug therapy; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Signal Transduction - drug effects; SREBPs; TOR Serine-Threonine Kinases - metabolism; VDAC1; Voltage-Dependent Anion Channel 1 - metabolism
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2023.155313

The occurrence of hyperlipidemia is significantly influenced by lipid synthesis, which is regulated by sterol regulatory element binding proteins (SREBPs), thus the development of drugs that inhibit lipid synthesis has become a popular treatment strategy for hyperlipidemia. Alisol B (ALB), a triterpenoid compound extracted from Alisma, has been reported to ameliorate no-nalcoholic steatohepatitis (NASH) and slow obesity. However, the effect of ALB on hyperlipidemia and mechanism are unclear. To examine the therapeutic impact of ALB on hyperlipidemia whether it inhibits SREBPs to reduce lipid synthesis. HepG2, HL7702 cells, and C57BL/6J mice were used to explore the effect of ALB on hyperlipidemia and the molecular mechanism in vivo and in vitro. Hyperlipidemia models were established using western diet (WD)-fed mice in vivo and oleic acid (OA)-induced hepatocytes in vitro. Western blot, real-time PCR and other biological methods verified that ALB regulated AMPK/mTOR/SREBPs to inhibit lipid synthesis. Cellular thermal shift assay (CETSA), molecular dynamics (MD), and ultrafiltration-LC/MS analysis were used to evaluate the binding of ALB to voltage-dependent anion channel protein-1 (VDAC1). ALB decreased TC, TG, LDL-c, and increased HDL-c in blood, thereby ameliorating liver damage. Gene set enrichment analysis (GSEA) indicated that ALB inhibited the biosynthesis of cholesterol and fatty acids. Consistently, ALB inhibited the protein expression of n-SREBPs and downstream genes. Mechanistically, the impact of ALB on SREBPs was dependent on the regulation of AMPK/mTOR, thereby impeding the transportation of SREBPs from endoplasmic reticulum (ER) to golgi apparatus (GA). Further investigations indicated that the activation of AMPK by ALB was independent on classical upstream CAMKK2 and LKB1. Instead, ALB resulted in a decrease in ATP levels and an increase in the ratios of ADP/ATP and AMP/ATP. CETSA, MD, and ultrafiltration-LC/MS analysis indicated that ALB interacted with VDAC1. Molecular docking revealed that ALB directly bound to VDAC1 by forming hydrogen bonds at the amino acid sites S196 and H184 in the ATP-binding region. Importantly, the thermal stabilization of ALB on VDAC1 was compromised when VDAC1 was mutated at S196 and H184, suggesting that these amino acids played a crucial role in the interaction. Our findings reveal that VDAC1 serves as the target of ALB, leading to the inhibition of lipid synthesis, presents potential target and candidate drug